Cite
NABNEC: A randomised phase II study of nab -paclitaxel in combination with carboplatin as first line treatment of gastrointestinal neuroendocrine carcinomas (GI-NECs).
MLA
Chantrill, Lorraine A., et al. “NABNEC: A Randomised Phase II Study of Nab -Paclitaxel in Combination with Carboplatin as First Line Treatment of Gastrointestinal Neuroendocrine Carcinomas (GI-NECs).” Journal of Clinical Oncology, vol. 42, Jan. 2024, p. 589. EBSCOhost, https://doi.org/10.1200/JCO.2024.42.3_suppl.589.
APA
Chantrill, L. A., Ransom, D., Chan, D., Nagrial, A., Pavlakis, N., Markman, B., Karapetis, C. S., Sjoquist, K. M., Simes, J., Gebski, V., Hofman, M. S., Ginestet, P. G., Gill, A. J., Yip, S., Michael, M., Jaworski, A., Siu, H. W. D., & Khasraw, M. (2024). NABNEC: A randomised phase II study of nab -paclitaxel in combination with carboplatin as first line treatment of gastrointestinal neuroendocrine carcinomas (GI-NECs). Journal of Clinical Oncology, 42, 589. https://doi.org/10.1200/JCO.2024.42.3_suppl.589
Chicago
Chantrill, Lorraine A., David Ransom, David Chan, Adnan Nagrial, Nick Pavlakis, Ben Markman, Christos Stelios Karapetis, et al. 2024. “NABNEC: A Randomised Phase II Study of Nab -Paclitaxel in Combination with Carboplatin as First Line Treatment of Gastrointestinal Neuroendocrine Carcinomas (GI-NECs).” Journal of Clinical Oncology 42 (January): 589. doi:10.1200/JCO.2024.42.3_suppl.589.